192 related articles for article (PubMed ID: 30897064)
1. Elevated FPR confers to radiochemoresistance and predicts clinical efficacy and outcome of metastatic colorectal cancer patients.
Chen QG; Zhang L; Sun F; Li SQ; You XH; Jiang YH; Yang WM; Zhong QH; Wang XZ; Ying HQ
Aging (Albany NY); 2019 Mar; 11(6):1716-1732. PubMed ID: 30897064
[TBL] [Abstract][Full Text] [Related]
2. The Role of Cancer-Elicited Inflammatory Biomarkers in Predicting Early Recurrence Within Stage II-III Colorectal Cancer Patients After Curable Resection.
Ying HQ; Liao YC; Sun F; Peng HX; Cheng XX
J Inflamm Res; 2021; 14():115-129. PubMed ID: 33500648
[TBL] [Abstract][Full Text] [Related]
3. Potential prognostic factors for predicting the chemotherapeutic outcomes and prognosis of patients with metastatic colorectal cancer.
Zhang L; Zhang J; Wang Y; Dong Q; Piao H; Wang Q; Zhou Y; Ding Y
J Clin Lab Anal; 2019 Oct; 33(8):e22958. PubMed ID: 31218745
[TBL] [Abstract][Full Text] [Related]
4. Combined fibrinogen-to-pre-albumin ratio and carbohydrate antigen 19-9 score is a promising metric to predict progression of metastatic colorectal mucinous adenocarcinoma.
Liao YC; Fu M; Wang XF; Cheng XX
J Clin Lab Anal; 2021 May; 35(5):e23757. PubMed ID: 33734488
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of a novel FPR biomarker in patients with surgical stage II and III gastric cancer.
Zhang J; Li SQ; Liao ZH; Jiang YH; Chen QG; Huang B; Liu J; Xu YM; Lin J; Ying HQ; Wang XZ
Oncotarget; 2017 Sep; 8(43):75195-75205. PubMed ID: 29088857
[TBL] [Abstract][Full Text] [Related]
6. The value of circulating fibrinogen-to-pre-albumin ratio in predicting survival and benefit from chemotherapy in colorectal cancer.
Ying HQ; Sun F; Liao YC; Cai D; Yang Y; Cheng XX
Ther Adv Med Oncol; 2021; 13():17588359211022886. PubMed ID: 34262615
[TBL] [Abstract][Full Text] [Related]
7. Quantification of fibrinogen-to-pre-albumin ratio provides an integrating parameter for differential diagnosis and risk stratification of early-stage colorectal cancer.
Ying HQ; Chen W; Xiong CF; Wang Y; Li XJ; Cheng XX
Cancer Cell Int; 2022 Mar; 22(1):137. PubMed ID: 35346200
[TBL] [Abstract][Full Text] [Related]
8. Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.
Ulivi P; Scarpi E; Chiadini E; Marisi G; Valgiusti M; Capelli L; Casadei Gardini A; Monti M; Ruscelli S; Frassineti GL; Calistri D; Amadori D; Passardi A
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28598398
[TBL] [Abstract][Full Text] [Related]
9. Preoperative circulating FPR and CCF score are promising biomarkers for predicting clinical outcome of stage II-III colorectal cancer patients.
Sun F; Peng HX; Gao QF; Li SQ; Zhang J; Chen QG; Jiang YH; Zhang L; Wang XZ; Ying HQ
Cancer Manag Res; 2018; 10():2151-2161. PubMed ID: 30050325
[TBL] [Abstract][Full Text] [Related]
10. High-Grade Inflammation Attenuates Chemosensitivity and Confers to Poor Survival of Surgical Stage III CRC Patients.
Ying HQ; You XH; Liao YC; Sun F; Cheng XX
Front Oncol; 2021; 11():580455. PubMed ID: 33968712
[No Abstract] [Full Text] [Related]
11. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
Bencsikova B; Budinska E; Selingerova I; Pilatova K; Fedorova L; Greplova K; Nenutil R; Valik D; Obermannova R; Sheard MA; Zdrazilova-Dubska L
BMC Cancer; 2019 Jul; 19(1):687. PubMed ID: 31307428
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.
Artaç M; Uysal M; Karaağaç M; Korkmaz L; Er Z; Güler T; Börüban MC; Bozcuk H
J Gastrointest Cancer; 2017 Jun; 48(2):176-180. PubMed ID: 27714653
[TBL] [Abstract][Full Text] [Related]
13. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
Snyder M; Bottiglieri S; Almhanna K
Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
[TBL] [Abstract][Full Text] [Related]
14. Circulating fibrinogen to pre-albumin ratio is a promising biomarker for diagnosis of colorectal cancer.
Sun F; Tan YA; Gao QF; Li SQ; Zhang J; Chen QG; Jiang YH; Zhang L; Ying HQ; Wang XZ
J Clin Lab Anal; 2019 Jan; 33(1):e22635. PubMed ID: 30047185
[TBL] [Abstract][Full Text] [Related]
15. Albumin-to-fibrinogen ratio as a promising biomarker to predict clinical outcome of non-small cell lung cancer individuals.
Li SQ; Jiang YH; Lin J; Zhang J; Sun F; Gao QF; Zhang L; Chen QG; Wang XZ; Ying HQ
Cancer Med; 2018 Apr; 7(4):1221-1231. PubMed ID: 29533009
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
[TBL] [Abstract][Full Text] [Related]
17. Role of Chronic Inflammatory Ratios in Predicting Recurrence of Resected Patients with Stage I-III Mucinous Colorectal Adenocarcinoma.
Liao YC; Ying HQ; Huang Y; Luo YR; Xiong CF; Nie RW; Li XJ; Cheng XX
Cancer Manag Res; 2021; 13():3455-3464. PubMed ID: 33907468
[TBL] [Abstract][Full Text] [Related]
18. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
19. Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.
Kratz JD; Uboha NV; Lubner SJ; Mulkerin DL; Clipson L; Yi Y; Yu M; Matkowskyj KA; LoConte NK; Deming DA
J Natl Compr Canc Netw; 2018 Dec; 16(12):1442-1450. PubMed ID: 30545991
[No Abstract] [Full Text] [Related]
20. Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings.
Houts AC; Ogale S; Zafar Y; Hubbard JM; Satram-Hoang S; Sommer N; Walker MS
J Gastrointest Cancer; 2019 Mar; 50(1):16-22. PubMed ID: 29058260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
